Senate Bill 775
118th Congress(2023-2024)
Increasing Transparency in Generic Drug Applications Act
Introduced
Introduced in Senate on Mar 14, 2023
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
775
Congress
118
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No Senate votes have been held for this bill.
Summary
Increasing Transparency in Generic Drug Applications Act
This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.
March 14, 2023
Sort by most recent
03/14/2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
03/14/2023
Introduced in Senate
Public Record
Record Updated
Apr 17, 2024 11:52:05 PM